Trade Abbott Laboratories - ABT CFD
Add to favourite- Summary
- Historical Data
Spread | 0.16 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.026235% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004012% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 116.71 |
Open | 116.27 |
1-Year Change | 13.67% |
Day's Range | 116 - 116.91 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Sep 13, 2024 | 116.33 | 0.93 | 0.81% | 115.40 | 116.97 | 115.35 |
Sep 12, 2024 | 116.71 | 0.78 | 0.67% | 115.93 | 117.24 | 115.45 |
Sep 11, 2024 | 116.50 | 0.19 | 0.16% | 116.31 | 116.65 | 114.63 |
Sep 10, 2024 | 116.96 | 1.78 | 1.55% | 115.18 | 117.18 | 114.95 |
Sep 9, 2024 | 116.36 | 2.43 | 2.13% | 113.93 | 116.66 | 113.93 |
Sep 6, 2024 | 113.86 | 0.76 | 0.67% | 113.10 | 114.25 | 112.84 |
Sep 5, 2024 | 113.03 | -0.74 | -0.65% | 113.77 | 114.33 | 112.45 |
Sep 4, 2024 | 114.32 | 0.39 | 0.34% | 113.93 | 115.49 | 113.49 |
Sep 3, 2024 | 114.59 | 1.77 | 1.57% | 112.82 | 114.76 | 112.82 |
Aug 30, 2024 | 113.20 | 0.73 | 0.65% | 112.47 | 113.41 | 111.82 |
Aug 29, 2024 | 112.70 | -0.10 | -0.09% | 112.80 | 113.38 | 112.45 |
Aug 28, 2024 | 112.83 | 0.36 | 0.32% | 112.47 | 113.11 | 112.29 |
Aug 27, 2024 | 113.04 | 0.46 | 0.41% | 112.58 | 113.11 | 112.04 |
Aug 26, 2024 | 112.62 | 0.15 | 0.13% | 112.47 | 113.18 | 111.95 |
Aug 23, 2024 | 112.61 | 0.78 | 0.70% | 111.83 | 112.71 | 111.68 |
Aug 22, 2024 | 112.05 | 0.50 | 0.45% | 111.55 | 112.07 | 110.97 |
Aug 21, 2024 | 111.33 | 0.65 | 0.59% | 110.68 | 111.40 | 110.59 |
Aug 20, 2024 | 110.41 | -0.53 | -0.48% | 110.94 | 111.96 | 110.26 |
Aug 19, 2024 | 111.83 | 1.69 | 1.53% | 110.14 | 112.18 | 110.05 |
Aug 16, 2024 | 110.91 | -0.08 | -0.07% | 110.99 | 111.30 | 110.50 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Abbott Company profile
What is Abbott Laboratories?
Abbott Laboratories is a US healthcare company that employs around 99,000 people and delivers its services in over 150 countries worldwide. Abbott produces and distributes a range of products under such popular brands as PediaSure, Glucerna, Similac, Absorb and others. Its mission statement is: “To improve lives by providing cost-effective health care products and services.”
The company focuses on the following healthcare segments: Nutrition, Vascular Care, Diabetes Care, Vision, Pharmaceuticals and Diagnostics. It advocates for innovation in medicine and works to improve vision correction, take heart health treatments to the next level and introduce innovative methods of diabetes management.
Abbott has also pioneered new ways to screen, diagnose and monitor a wide range of health conditions with greater speed and accuracy. In pharmaceuticals, the company has revolutionised packaging and delivery to meet regional needs and offer access to medicines in areas that once lacked them.
Who are the key people at Abbott Laboratories?
Miles D. White is Chairman and Chief Executive Officer of Abbott. He has held both roles since 1999, and first joined the company back in 1984. Another key figure at Abbott Laboratories is Brian Blaser, Executive Vice President, Diagnostics Products. He leads Abbott's diagnostics, molecular and point-of-care businesses. Robert Ford is Executive Vice President, Medical Devices.
What is the modern history of Abbott Laboratories?
Abbott was incorporated in 1894, and its initial public offering took place in 1929. Among a number of landmark developments in the second half of the 20th century was the acquisition of M&R Dietetics in 1964, which made the company a leader in nutrition. Abbott’s modern diagnostics business took off in the early 1970s, and in 1985 the FDA approved the firm’s test to identify HIV in blood. In 1998 Abbott introduced Glucerna – a range of snack bars and shakes for diabetics. The first decade of the 21st century saw FDA approval of antibody drug Humira, which became the world’s leading pharmaceutical product.
What are the latest developments at Abbott Laboratories?
In January 2017 Abbott completed the acquisition of St Jude Medical – a development which put the company in a leading position in the medical devices sector. Abbott now holds the No.1 or No.2 positions in nearly every segment of the $30 billion cardiovascular market. In 2017 Abbott also recorded 40 per cent growth in its neuromodulation business, attaining the No.1 spot in spinal cord neurostimulation.
In February 2018, Abbott announced a licensing deal with mid-tech firm Surmodics Inc that could be worth up to $92 million. Under the agreement, Surmodics will exclusively license its SurVeil drug-coated balloon device to Abbott. Surmodics is testing it as a treatment for peripheral artery disease.
Since the start of 2015, the Abbott share price has ranged from a low of around $37 in February 2016 to over $60 in January 2018. The company’s market capitalisation on 2 March 2018 was $103.5 billion. Our ABT chart tracks Abbott’s recent share price movements.
Where does Abbott Laboratories operate?
Abbott is headquartered in Chicago, Illinois. It has a truly global presence, with operations across the Americas, Europe and Asia Pacific – including China, India, Japan, Australia and New Zealand.
Where is Abbott Laboratories traded?
Abbott Laboratories is listed on the New York Stock Exchange. As of 2017, the shares were mainly held by institutional investors such as BlackRock, State Street Corporation and The Vanguard Group. Check out Capital.com for the latest ABT chart.
Industry: | Medical Equipment, Supplies & Distribution (NEC) |
100 Abbott Park Rd
ABBOTT PARK
ILLINOIS 60064-3500
US
News
ECB Preview: cuts expected but the pace is uncertain
Markets expect the ECB to cut rates again in September, but how many more?
12:34, 11 September 2024Market analysis: US CPI and PPI
Overview of upcoming US inflation data for August, with expectations for a year-over-year CPI drop to 2.6% and core CPI holding steady at 3.2%. Markets will also focus on U.S. PPI data, which is forecasted to show mild growth, reinforcing potential easing inflationary pressures.
07:56, 10 September 2024Introducing Newsquawk: your new in-platform newsfeed
We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.
14:09, 20 August 2024Jackson Hole Preview: All eyes on Powell and Gold
The key focus this week will be on Jerome Powell and any insight he may give into the future of monetary policy.
15:24, 19 August 2024All eyes on inflation: US and UK CPI take centre stage
Just over a month has gone by since the latest CPI data was released in the US and so much has happened since.
14:41, 13 August 2024European stocks face resistance in their attempt to recover
European stocks struggle to recover as the tech sector faces continued downside pressure in Asia.
13:56, 9 August 2024Global selloff continues on US economy fears
Thursday’s rise in jobless claims led to a market meltdown in the US stock market as investors became concerned that the Federal Reserve made the wrong decision by keeping rates unchanged on Wednesday.
14:40, 5 August 2024People also watch
Still looking for a broker you can trust?
Join the 640,000+ traders worldwide that chose to trade with Capital.com